Ace Therapeutics offers specialized biomarker analysis services exclusively focused on advancing drug discovery and preclinical development for Liver Injury research. Our comprehensive biomarker panel is designed to provide deep insights into the molecular and cellular mechanisms underlying liver injury, supporting the rational development of novel therapeutics. Please note that all our services are strictly limited to the research and preclinical space and do not include clinical diagnostic offerings.
The foundation of effective therapeutic intervention lies in the precise identification and characterization of disease-relevant biomarkers. At Ace Therapeutics, our biomarker discovery services encompass the systematic screening and identification of molecular signatures associated with Liver Injury. Through advanced analytical and computational approaches, we identify candidate biomarkers that inform target validation, mechanism-of-action studies, and efficacy assessments. Rigorous screening and validation processes ensure that only the most promising biomarker candidates are prioritized for further development, maximizing translational relevance in preclinical drug discovery.
Multi Omics: Our multi-omics approach leverages state-of-the-art genomics, transcriptomics, proteomics, and metabolomics technologies to enable a comprehensive study of biological systems relevant to Liver Injury. By integrating high-throughput sequencing, quantitative PCR, mass spectrometry, and multiplex immunoassays, we identify and characterize DNA, RNA, protein, and metabolite biomarkers. This systems-level analysis facilitates the elucidation of key disease pathways, including oxidative stress response, apoptosis, inflammation, and immune activation, all of which are central to the pathophysiology of Liver Injury.
Candidate Validation: Candidate biomarker validation at Ace Therapeutics involves a multi-tiered strategy, including rigorous association studies with Liver Injury pathophysiology, robust preliminary screening, and prioritization based on biological relevance and analytical performance. Criteria for selecting promising candidates include reproducibility, specificity to liver injury processes, dynamic range in relevant models, and feasibility of assay development. This ensures that only biomarkers with strong mechanistic links and translational potential advance through our pipeline.
Diverse Technological Platforms: We offer custom assay development tailored to the unique requirements of each biomarker, adapting our platforms to accommodate analyte type, sample matrix, and throughput needs. Our capabilities span immunoassays, mass spectrometry, flow cytometry, molecular diagnostics, and advanced histopathology and imaging, enabling flexible and precise measurement of diverse biomarker classes.
Immunoassays: We develop and implement enzyme-linked immunosorbent assays (ELISA), chemiluminescent immunoassays, and multiplex bead-based platforms for sensitive and quantitative protein detection.
Mass Spectrometry: Our LC-MS/MS platforms enable high-resolution, quantitative analysis of proteins, peptides, metabolites, and small molecules relevant to liver injury.
Flow Cytometry: We utilize flow cytometry for cellular phenotyping and quantification of surface and intracellular biomarkers in liver and immune cell populations.
Molecular Diagnostics: We employ quantitative PCR, digital PCR, and next-generation sequencing for the detection and quantification of nucleic acid biomarkers such as microRNAs and gene transcripts.
Histopathology And Imaging: Advanced histopathological staining, immunohistochemistry, and imaging techniques are used to localize and quantify biomarkers within liver tissue architecture.
Rigorous Method Validation: All analytical methods undergo rigorous validation in accordance with established research guidelines, including assessment of accuracy, precision, sensitivity, specificity, linearity, and reproducibility. Quality control measures are implemented at every stage to ensure robust and reliable data generation, supporting the integrity of preclinical biomarker research.
Our quantitative analysis capabilities enable precise measurement of biomarker levels across a broad dynamic range. We apply validated protocols and calibration standards to ensure data accuracy, supporting the assessment of biomarker modulation in response to therapeutic interventions in preclinical models.
Sample Analysis: Ace Therapeutics processes a wide variety of sample types, including serum, plasma, liver tissue, and cell lysates. Stringent protocols govern sample handling, preparation, and analysis to minimize variability and maximize data quality. Quality assurance procedures are embedded throughout the workflow to ensure sample integrity and reproducibility of results.
High Throughput Capabilities: Our high-throughput analytical platforms, including multiplex immunoassays and automated sample processing systems, enable the simultaneous analysis of multiple biomarkers from limited sample volumes. This approach enhances efficiency, conserves valuable samples, and accelerates the generation of comprehensive biomarker profiles for Liver Injury research.
| Gene Target | Biological Function | Application as a Biomarker |
|---|---|---|
| BCL2 associated X, apoptosis regulator (BAX) | BCL2 associated X, apoptosis regulator (BAX) is a pro-apoptotic member of the BCL-2 protein family. BAX plays a critical role in the regulation of programmed cell death (apoptosis) by promoting mitochondrial outer membrane permeabilization. Upon activation by cellular stress signals, BAX undergoes a conformational change, translocates to the mitochondria, and facilitates the release of cytochrome c and other pro-apoptotic factors into the cytosol. This process leads to the activation of downstream caspases and ultimately results in cell death. BAX is tightly regulated and functions as a key effector in the intrinsic (mitochondrial) apoptotic pathway, balancing cell survival and death in response to physiological and pathological stimuli. | BAX expression levels have been investigated as a biomarker in various contexts, particularly in oncology. Altered BAX expression has been associated with tumor progression, response to chemotherapy, and prognosis in several cancer types. Immunohistochemical and molecular analyses of BAX can provide information about the apoptotic potential of tumor cells, as decreased BAX expression may indicate resistance to apoptosis-inducing therapies. Additionally, BAX is studied as part of gene expression panels to assess apoptotic activity in tissues, contributing to research on disease mechanisms and therapeutic responses. |
| NFE2 like bZIP transcription factor 2 (NFE2L2) | NFE2 like bZIP transcription factor 2 (NFE2L2), also known as NRF2, is a transcription factor that plays a central role in cellular defense against oxidative and electrophilic stress. Under basal conditions, NFE2L2 is sequestered in the cytoplasm by its inhibitor KEAP1 and targeted for proteasomal degradation. Upon exposure to oxidative stress or electrophilic agents, NFE2L2 dissociates from KEAP1, translocates to the nucleus, and binds to antioxidant response elements (ARE) in the promoter regions of target genes. This leads to the transcriptional activation of a battery of cytoprotective genes involved in antioxidant defense, detoxification, and cellular redox homeostasis, including genes encoding glutathione synthesis enzymes, NAD(P)H:quinone oxidoreductase 1 (NQO1), and heme oxygenase-1 (HO-1). | NFE2L2 expression and activity have been investigated as biomarkers in various contexts, particularly for assessing oxidative stress response and cellular adaptation to electrophilic insults. Alterations in NFE2L2 signaling, such as increased nuclear localization, gene expression, or pathway activation, have been reported in multiple diseases, including cancer, neurodegenerative disorders, and chronic inflammatory conditions. In oncology, NFE2L2 pathway activation has been associated with tumor progression and resistance to chemotherapy. In environmental and toxicological studies, NFE2L2 target gene induction is used as a readout for cellular oxidative stress responses. |
| NLR family pyrin domain containing 3 (NLRP3) | NLR family pyrin domain containing 3 (NLRP3) is a cytosolic pattern recognition receptor that plays a central role in the innate immune system. NLRP3 is a component of the NLRP3 inflammasome, a multiprotein complex that detects a wide range of pathogen-associated molecular patterns (PAMPs) and danger-associated molecular patterns (DAMPs). Upon activation by various stimuli, NLRP3 oligomerizes and recruits the adaptor protein ASC (apoptosis-associated speck-like protein containing a CARD), which in turn recruits and activates caspase-1. Activated caspase-1 processes pro-inflammatory cytokines, such as interleukin-1β (IL-1β) and interleukin-18 (IL-18), into their mature forms and induces a form of cell death known as pyroptosis. Through these mechanisms, NLRP3 contributes to host defense and inflammation. | NLRP3 expression and activation status have been investigated as biomarkers for inflammatory and immune-mediated conditions. Elevated levels of NLRP3 or its inflammasome components have been associated with diseases characterized by excessive inflammation, including autoinflammatory syndromes, metabolic disorders, and certain neurodegenerative diseases. Measurement of NLRP3 or related inflammasome activity in tissues or peripheral blood has been explored to assess disease activity, monitor progression, or evaluate response to anti-inflammatory therapies. |
| interleukin 1 beta (IL1B) | Interleukin 1 beta (IL1B) is a pro-inflammatory cytokine produced primarily by activated macrophages, as well as other cell types including monocytes, dendritic cells, and epithelial cells. It plays a central role in the regulation of immune and inflammatory responses. IL1B is synthesized as an inactive precursor (pro-IL1B) and is cleaved by caspase-1 to generate the active form. Upon secretion, IL1B binds to the interleukin-1 receptor (IL-1R), leading to the activation of downstream signaling pathways such as NF-κB and MAPK, which promote the expression of additional inflammatory mediators. IL1B is involved in processes such as fever induction, leukocyte recruitment, and the activation of endothelial cells, contributing to both local and systemic inflammatory responses. | IL1B has been studied as a biomarker for various inflammatory and infectious conditions. Elevated levels of IL1B in serum, plasma, or tissue samples have been associated with diseases characterized by inflammation, including rheumatoid arthritis, sepsis, inflammatory bowel disease, and certain autoinflammatory syndromes. Its measurement is utilized in research and clinical studies to assess the extent of inflammation, monitor disease activity, and evaluate responses to anti-inflammatory therapies. |
| interleukin 6 (IL6) | Interleukin 6 (IL6) is a multifunctional cytokine produced by a variety of cell types, including T cells, B cells, monocytes, fibroblasts, and endothelial cells. IL6 plays a central role in the regulation of immune responses, hematopoiesis, inflammation, and the acute-phase reaction. It acts through binding to its receptor complex, which consists of IL6R (interleukin 6 receptor) and gp130, leading to the activation of intracellular signaling pathways such as JAK/STAT, MAPK, and PI3K/Akt. IL6 is involved in the differentiation of B cells into antibody-producing plasma cells, the stimulation of hepatocytes to produce acute-phase proteins, and the modulation of T cell responses. It also contributes to the regulation of metabolic, regenerative, and neural processes. | IL6 is commonly measured in biological fluids such as serum or plasma as an indicator of inflammatory activity. Elevated IL6 levels have been associated with a variety of conditions characterized by inflammation or immune activation, including infectious diseases, autoimmune disorders, and certain cancers. In clinical and research settings, IL6 concentrations are used to monitor disease activity, assess the severity of inflammatory responses, and evaluate the effects of therapeutic interventions targeting inflammation. |
| microRNA 122 (MIR122) | microRNA 122 (MIR122) is a highly abundant, liver-specific microRNA that plays a critical role in the regulation of hepatic gene expression. It is involved in various aspects of liver physiology, including lipid metabolism, cholesterol biosynthesis, and the modulation of hepatocyte differentiation. MIR122 also influences the stability and translation of target messenger RNAs by binding to their 3' untranslated regions, thereby regulating gene expression post-transcriptionally. Additionally, MIR122 has been shown to affect the replication of certain viruses, such as hepatitis C virus, by directly interacting with viral RNA. | MIR122 is widely studied as a circulating biomarker for liver injury and disease. Its levels in blood or serum are elevated in response to hepatocellular damage, making it a useful indicator in the context of acute liver injury, drug-induced liver toxicity, and various liver diseases such as viral hepatitis and non-alcoholic fatty liver disease. Measurement of MIR122 in biological fluids has been explored for its potential to provide sensitive and specific information about liver health and the extent of hepatocyte damage. |
| microRNA 21 (MIR21) | microRNA 21 (MIR21) is a small, non-coding RNA molecule that functions primarily as a post-transcriptional regulator of gene expression. MIR21 is transcribed from the MIR21 gene and incorporated into the RNA-induced silencing complex (RISC), where it binds to complementary sequences in the 3' untranslated regions (UTRs) of target messenger RNAs (mRNAs). This binding leads to mRNA degradation or translational inhibition. MIR21 is known to regulate multiple cellular processes, including cell proliferation, apoptosis, differentiation, and migration. It exerts its effects by targeting a variety of genes implicated in tumor suppression, apoptosis (such as PTEN and PDCD4), and other signaling pathways. MIR21 is widely expressed in various tissues and is notably upregulated in response to cellular stress and in pathological conditions, particularly in cancer. | MIR21 has been studied as a biomarker due to its consistent overexpression in a range of malignancies, including breast, lung, colorectal, and gastric cancers. Its presence and elevated levels have been detected in tumor tissues as well as in body fluids such as blood and urine. MIR21 expression levels have been investigated for their association with disease diagnosis, prognosis, and therapeutic response. In addition to cancer, altered MIR21 expression has been explored in the context of cardiovascular diseases, inflammatory conditions, and fibrosis. Its stability in biological specimens and detectability by quantitative PCR and other molecular techniques support its application in biomarker research. |
| prostaglandin-endoperoxide synthase 2 (PTGS2) | Prostaglandin-endoperoxide synthase 2 (PTGS2), also known as cyclooxygenase-2 (COX-2), is an inducible enzyme that catalyzes the conversion of arachidonic acid to prostaglandin H2, a precursor of various prostanoids including prostaglandins and thromboxanes. PTGS2 is primarily expressed at sites of inflammation and is regulated by cytokines, growth factors, and other stimuli. Its activity leads to the production of pro-inflammatory mediators, contributing to processes such as inflammation, pain, and fever. Unlike the constitutively expressed PTGS1 (COX-1), PTGS2 is typically undetectable in most tissues under physiological conditions but is rapidly upregulated in response to inflammatory signals. | PTGS2 expression has been utilized as a biomarker for inflammation and is frequently assessed in the context of various diseases, including cancer, rheumatoid arthritis, and neurodegenerative disorders. Elevated PTGS2 levels in tissue samples or body fluids have been associated with inflammatory responses and tumorigenesis. In oncology, increased PTGS2 expression in tumor tissues has been correlated with tumor progression, angiogenesis, and poor prognosis in several cancer types. Additionally, PTGS2 is a target for nonsteroidal anti-inflammatory drugs (NSAIDs), and its expression is monitored to evaluate the inflammatory status and potential therapeutic responses. |
| toll like receptor 4 (TLR4) | Toll-like receptor 4 (TLR4) is a pattern recognition receptor that plays a central role in the innate immune system. It is primarily expressed on immune cells such as macrophages, dendritic cells, and neutrophils. TLR4 recognizes lipopolysaccharide (LPS), a major component of the outer membrane of Gram-negative bacteria, as well as other pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs). Upon ligand binding, TLR4 initiates intracellular signaling cascades that lead to the activation of transcription factors such as NF-κB and the production of pro-inflammatory cytokines, chemokines, and type I interferons. This response is critical for the early detection of infection and the initiation of inflammatory and immune responses. | TLR4 expression and signaling activity have been investigated as biomarkers of immune activation and inflammation in various clinical contexts. Elevated TLR4 levels or altered signaling have been associated with infectious diseases, sepsis, autoimmune disorders, and certain cancers. Measurement of TLR4 expression or the detection of TLR4 gene polymorphisms is used in research and clinical studies to assess immune status, disease susceptibility, and prognosis. |
| tumor necrosis factor (TNF) | Tumor necrosis factor (TNF), also known as TNF-alpha, is a pro-inflammatory cytokine primarily produced by activated macrophages, as well as other immune cells such as T lymphocytes and natural killer cells. TNF plays a central role in mediating inflammation, immune system regulation, and apoptosis. It is involved in the activation of signaling pathways such as NF-κB and MAPK, leading to the expression of various inflammatory mediators. TNF contributes to the recruitment of immune cells to sites of infection or injury, enhances the phagocytic activity of macrophages, and can induce cell death in certain target cells. It is also implicated in the pathogenesis of several autoimmune and inflammatory diseases. | TNF levels have been measured in biological fluids such as serum, plasma, and synovial fluid as an indicator of inflammatory activity. Elevated TNF concentrations have been associated with a range of conditions, including rheumatoid arthritis, inflammatory bowel disease, sepsis, and certain malignancies. Its quantification can be used to assess disease activity, monitor response to anti-TNF therapies, and provide supportive information regarding the presence and severity of inflammation in clinical and research settings. |
Explore Research Opportunities with Ace Therapeutics. Our biomarker research services offer advanced capabilities for the discovery, validation, and analysis of molecular targets relevant to Liver Injury in preclinical drug development. All biomarkers discussed are research targets only; we do not claim any as validated or mandatory for any indication. Our services are strictly exploratory and focused on the preclinical research stage, maintaining scientific objectivity and supporting the advancement of knowledge in liver injury pathophysiology.
We invite you to engage with Ace Therapeutics for collaborative discussions on biomarker research in Liver Injury. Our focus is on the exploratory and scientific advancement of biomarker discovery and analysis. Let us work together to exchange knowledge and drive innovation in preclinical research.
Make Order
Experimental Scheme
Implementation
Conclusion